Вакцинопроизводитель из Оксфорда близок к банкротству из-за долга в 430 тысяч фунтов

An Oxford University vaccine firm is near collapse amid £430K debt reported in its latest accounts. A meeting has been held for the creditors of Oxford Vacmedix UK Limited, a company based at Oxford Science Park. It was held on September 1 having been called to decide whether a liquidator is to be appointed for the firm, which specialises in research and experimental development on biotechnology. The outcome is not yet known. A statement on The Gazette (the official government website) said that the meeting had been called for the "purposes mentioned in Section 100 of the Insolvency Act 1986". READ MORE: Oxford HMO property with licence for 16 listed for £1.45 million sale Under this section the company or the company's creditors may nominate a person to be a liquidator at the meeting, with a creditors voluntary liquidation being mooted. Established as a spinout from Oxford University in September 2012, Oxford Vacmedix aims to develop therapeutic agents for the treatment of cancer. It says on its website that it is developing an "exciting new way to deliver immunotherapy which is now a major focus in the treatment of cancer". Immunotherapy is a type of medical treatment that uses your body's own immune system to fight diseases such as cancer. Oxford Vacmedix says it is using a new technology that significantly enhances the ability of a vaccine or a biologic drug to trigger an immune response in the body. A timeline on its website reveals that it started pre-clinical development in March 2018, following an investment of $12.5m USD. Clinical trials began in 2021 with more money invested in November 2024. In its latest accounts for the year ended December 31, 2024, it listed creditors falling within one year of £429,363. In addition it said the financial statements were prepared on a "going concern basis", meaning that it is assumed that it will continue in operation for the next year. READ MORE: UK fashion brand in another shop closure after Oxford Westgate announcement The account statement said: "The Company has incurred significant research and development expenses resulting in losses since its inception, and it expects to incur operating losses in future periods due to its stage of clinical development." It added: "Having reviewed the cash flow forecast for at least the 12-month period following the date of signing of these financial statements, the Directors have identified that additional cash will need to be raised to fund the activities of company beyond this 12-month period. "At the date of this report, further funds have not yet been secured." The average number of employees for the period was listed as six. Oxford Vacmedix and liquidators Crowe UK LLP have been approached for comment.